Posted by Michael Wonder on 19 Nov 2022
Iveric Bio announces FDA has granted breakthrough therapy designation for avacincaptad pegol for geographic atrophy
17 November 2022 - Designation based on 12 month primary endpoint data from GATHER pivotal trials.
IVERIC bio today announced that the US FDA has granted breakthrough therapy designation for avacincaptad pegol (ACP, also known as Zimura), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy secondary to age-related macular degeneration.
